A team of researchers led by Dr. Kim V. Narry, director of the Center for RNA Research at the Institute for Basic Science ...

Analysts have set 12-month price targets for Millicom Intl Cellular, revealing an average target of $35.98, a high estimate ...

Enduring a week’s worth of cold water plunges can jolt the body’s cells into starting the process of autophagy to clean up ...

Florey researchers have engineered a way to fool the immune system into accepting neural grafts as part of the body, rather ...

For patients with polycystic kidney disease (PKD), a common genetic disorder that ravages the waste-removing organ with cysts ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $126.67, along ...

Apple is already looking beyond its next generation of M-class chip, designing the future M6 processor that will include an ...

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report)‘s stock had its “neutral” rating reaffirmed by research analysts at ...

I’ve used iPad Pro as my primary computer for a decade, and despite being Mac-curious, here’s why I need to stick with the iPad (for now).

Researchers are studying why the energy factories are moving between cells and whether the process can be harnessed to treat ...

As spring invites a season of renewal, Board-Certified Family Medicine Physician and author Dr. Joseph Mercola is encouraging ...

Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth, discusses strategies for managing costs of novel cellular and gene therapies in the oncology pipeline.